ICI-170809
ICI-170809, also known as ZM-170809, is a selective serotonin 5-HT 2 receptor antagonist which was under development for the treatment of major depressive disorder, arrhythmias, thrombosis, and ischemic heart disorders but was never…
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
ICI-170809, also known as ZM-170809, is a selective serotonin 5-HT 2 receptor antagonist which was under development for the treatment of major depressive disorder, arrhythmias, thrombosis, and ischemic heart disorders but was never marketed. It was being developed by AstraZeneca. The drug reached phase 2 clinical trials prior to the discontinuation of its development.
See also
List of investigational antidepressants
Text derived from https://en.wikipedia.org/w/index.php?oldid=1328696130 under CC BY-SA 4.0; modifications have been made.